SÚKL's November IPLP list folds in radiopharmaceutical and ATMP measures

What happened

On 30 October 2026, SÚKL, the Czech State Institute for Drug Control, published its list of individually prepared medicinal products (IPLP) valid from 1 November 2026. According to the authority's notice, the November edition incorporates two general-nature measures. One concerns radiopharmaceuticals and the other concerns an advanced therapy medicinal product (ATMP).

The list sits in the price and reimbursement section of SÚKL's website, which is where market access teams already look for monthly Czech updates. It is a routine, periodic publication. What stands out this month is the inclusion of two product categories that rarely follow standard pricing and reimbursement logic: radiopharmaceuticals and ATMPs.

What the record does not tell us

The available information is a short summary. It does not name the radiopharmaceuticals or the ATMP concerned. It does not say what the measures change, whether that means a new listing, an amendment or a removal, or whether any price, reimbursement or conditions of use are affected. It also does not say whether the two measures were adopted together or at different times.

Until the full list and the underlying measures are read, any assessment of commercial impact would be speculation. The practical first step is to open the November document and check it against your own Czech portfolio and pipeline.

Why it matters for market access

Radiopharmaceuticals and ATMPs share a structural problem. They are often produced in small batches, close to the patient or on a patient-specific basis. They also have short shelf lives and specialised handling needs. As a result, they can sit awkwardly within the reimbursement frameworks designed for conventional, centrally manufactured medicines. A national list that addresses both categories in the same monthly update is therefore worth a close read, even if the individual changes turn out to be technical.

For manufacturers, the relevant questions are concrete. Does a listed measure affect a product you supply or plan to supply in Czechia? Does it alter how the product is classified, handled or documented at national level? For hospital and nuclear medicine stakeholders, the question is whether access routes have changed. The record supports none of these answers yet, but they are the right questions to put to the full text.

Context: a day of access and supply signals

The Czech update appeared alongside several other national notices on the same day. They are unrelated to it, but together they show how much access depends on national administrative decisions.

In Italy, AIFA's update of its innovative medicines list to 30 September 2026 recorded no new innovativeness recognitions. It also confirmed that belantamab mafodotin (Blenrep) and inavolisib (Itovebi) were refused innovative status for their assessed indications. Because the status is a national designation, a refusal matters for teams planning Italian launches. The records do not give AIFA's reasoning.

In Denmark, DKMA published supply notices saying GlaxoSmithKline Pharma A/S will permanently withdraw Flolan 500 microgram and Flolan 1.5 mg (epoprostenol infusion powder) for commercial reasons. The withdrawals are expected from late December 2027. That is a long lead time, and it gives clinicians and payers room to plan.

In Portugal, Infarmed said limited stock of flu vaccines for prescription dispensing in community pharmacies reflects a European shortage. It recommended that valid prescriptions be accepted, and urged pharmacies to prioritise campaign groups.

Who is affected and what to watch

Most directly affected are companies with radiopharmaceutical or ATMP products in Czechia, along with the pharmacies and hospital units that prepare or handle individually prepared products. Others who may be affected are Czech payers and distributors that rely on SÚKL's list. Teams without Czech exposure may still use the update as a prompt to review how national frameworks in their own markets treat such products.

Three things are worth watching. First, whether the content of the two measures becomes clearer through SÚKL's documentation or through stakeholder commentary. Second, whether further changes follow in the December list. Third, whether similar national adjustments for radiopharmaceuticals and ATMPs appear elsewhere. None of these is confirmed in the records, so treat them as monitoring points rather than forecasts.